GH (Guardant Health, Inc.) Stock Financials & Earnings

GHGuardant Health, Inc.

Mkt Cap$12B

Revenue (TTM)$982M

Net Income (TTM)-$416M

EPS (TTM)-$3.31

Free Cash Flow (TTM)-$221M

Gross Margin64.5%

Op. Margin-44.5%

Net Margin-42.4%

FCF Margin-22.5%

P/S Ratio (TTM)12.2x

P/E Ratio (TTM)—

YoY Rev Growth+32.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$129M	$76M	-$134M
Q2 23	$137M	$83M	-$120M
Q3 23	$143M	$85M	-$114M
Q4 23	$155M	$236M	-$198M
Q1 24	$168M	$103M	-$100M
Q2 24	$177M	$105M	-$101M
Q3 24	$191M	$117M	-$117M
Q4 24	$202M	$124M	-$126M
Q1 25	$203M	$129M	-$111M
Q2 25	$232M	$151M	-$106M
Q3 25	$265M	$172M	-$99M
Q4 25	$281M	$182M	-$121M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$93M	$40M	$76M
Q2 23	$90M	$42M	$71M
Q3 23	$94M	$36M	$69M
Q4 23	$90M	$38M	$79M
Q1 24	$84M	$39M	$80M
Q2 24	$83M	$40M	$82M
Q3 24	$87M	$49M	$98M
Q4 24	$94M	$52M	$105M
Q1 25	$89M	$47M	$104M
Q2 25	$87M	$50M	$120M
Q3 25	$90M	$53M	$127M
Q4 25	$98M	$61M	$143M

Revenue Segments

Quarter	Biopharma & Data	Licensing & Other	Oncology	Screening
Q1 25	$45M	$2M	$151M	$6M
Q2 25	$56M	$3M	$159M	$15M
Q3 25	$55M	$2M	$184M	$24M
Q4 25	$54M	$2M	$190M	$35M

Revenue by Geography

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$224M	$713M	$937M
Q2 23	$271M	$954M	$1.2B
Q3 23	$457M	$697M	$1.2B
Q4 23	$1.1B	$35M	$1.2B
Q1 24	$1.1B	$0	$1.1B
Q2 24	$1.0B	$0	$1.0B
Q3 24	$688M	$311M	$999M
Q4 24	$526M	$314M	$840M
Q1 25	$699M	$0	$699M
Q2 25	$629M	$0	$629M
Q3 25	$580M	$0	$580M
Q4 25	$378M	$823M	$1.2B

Shares Outstanding

Revenue Per Employee

Revenue / Employee